Cargando…

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients

Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to infl...

Descripción completa

Detalles Bibliográficos
Autores principales: ROŽMAN, SAMO, NOVAKOVIĆ, SRDJAN, GRABNAR, IZTOK, CERKOVNIK, PETRA, NOVAKOVIĆ, BARBARA JEZERŠEK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/
https://www.ncbi.nlm.nih.gov/pubmed/27123112
http://dx.doi.org/10.3892/ol.2016.4402
_version_ 1782428346021314560
author ROŽMAN, SAMO
NOVAKOVIĆ, SRDJAN
GRABNAR, IZTOK
CERKOVNIK, PETRA
NOVAKOVIĆ, BARBARA JEZERŠEK
author_facet ROŽMAN, SAMO
NOVAKOVIĆ, SRDJAN
GRABNAR, IZTOK
CERKOVNIK, PETRA
NOVAKOVIĆ, BARBARA JEZERŠEK
author_sort ROŽMAN, SAMO
collection PubMed
description Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to influence rituximab binding to FcγR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact of FcγRIIa and FcγRIIIa polymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B-cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted for FcγRIIa-27, FcγRIIa-131, FcγRIIIa-48 and FcγRIIIa-158 polymorphisms. The median follow-up time was 29.7 months (range, 9.7–45.4 months). No significant impact of the genotypes was observed on the treatment response, progression-free or overall survival of DLBCL patients. There was a non-significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val at FCγIIIa-158 compared to Phe carriers. The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients.
format Online
Article
Text
id pubmed-4841119
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-48411192016-04-27 The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients ROŽMAN, SAMO NOVAKOVIĆ, SRDJAN GRABNAR, IZTOK CERKOVNIK, PETRA NOVAKOVIĆ, BARBARA JEZERŠEK Oncol Lett Articles Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to influence rituximab binding to FcγR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact of FcγRIIa and FcγRIIIa polymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B-cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted for FcγRIIa-27, FcγRIIa-131, FcγRIIIa-48 and FcγRIIIa-158 polymorphisms. The median follow-up time was 29.7 months (range, 9.7–45.4 months). No significant impact of the genotypes was observed on the treatment response, progression-free or overall survival of DLBCL patients. There was a non-significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val at FCγIIIa-158 compared to Phe carriers. The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients. D.A. Spandidos 2016-05 2016-04-01 /pmc/articles/PMC4841119/ /pubmed/27123112 http://dx.doi.org/10.3892/ol.2016.4402 Text en Copyright: © Rožman et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
ROŽMAN, SAMO
NOVAKOVIĆ, SRDJAN
GRABNAR, IZTOK
CERKOVNIK, PETRA
NOVAKOVIĆ, BARBARA JEZERŠEK
The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
title The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
title_full The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
title_fullStr The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
title_full_unstemmed The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
title_short The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
title_sort impact of fcγriia and fcγriiia gene polymorphisms on responses to rchop chemotherapy in diffuse large b-cell lymphoma patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841119/
https://www.ncbi.nlm.nih.gov/pubmed/27123112
http://dx.doi.org/10.3892/ol.2016.4402
work_keys_str_mv AT rozmansamo theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT novakovicsrdjan theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT grabnariztok theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT cerkovnikpetra theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT novakovicbarbarajezersek theimpactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT rozmansamo impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT novakovicsrdjan impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT grabnariztok impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT cerkovnikpetra impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients
AT novakovicbarbarajezersek impactoffcgriiaandfcgriiiagenepolymorphismsonresponsestorchopchemotherapyindiffuselargebcelllymphomapatients